Abstract
The proposal to elevate the biosafety level of the laboratory from BSL2 to BSL3 aims to expand research capacity, enabling the study of high-risk viruses such as SARS-CoV-2, Mpox, and H5N1, as well as facilitating preclinical trials and the development of antiviral therapies and vaccines. The expansion will also allow the use of advanced high-throughput screening technologies for new comp…